{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-009627","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.649452+00:00","generated_at":"2026-05-27T22:47:19.285498+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aptose gets Nasdaq delisting notice for low bid price; reverse split vote Jan 27","bullets":["Received Staff letter Jan 14, 2025 for failing $1 minimum bid price for 30 consecutive days.","Must regain compliance by March 31, 2025 or present plan to hearings panel.","Special shareholders' meeting Jan 27, 2025 to approve reverse stock split.","Common shares continue to trade on TSX; unaffected by Nasdaq status.","No assurance of regaining compliance with Nasdaq listing rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-009627","json":"https://secwatch.observer/filing/0001193125-25-009627.json","markdown":"https://secwatch.observer/filing/0001193125-25-009627.md","text":"https://secwatch.observer/filing/0001193125-25-009627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/d877128d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:47:19.285498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b84f621bd6c3f225ff83ec19918da8637df19510","claim":"Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001654954-26-005548","ticker":"ONFO","company_name":"Onfolio Holdings, Inc","filed_at":"2026-05-29T20:30:53+00:00","headline":"Onfolio receives Nasdaq delisting notice for insufficient equity ($1.22M vs $2.5M min)","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-005548","json":"https://secwatch.observer/filing/0001654954-26-005548.json","markdown":"https://secwatch.observer/filing/0001654954-26-005548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/0001654954-26-005548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/onfo_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 26, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Quarterly Report on Form 10-Q for the for the period ended March 31, 2026 reported stockholders’ equity of $1,216,603. As of the date of the Notice","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/0001654954-26-005548-index.htm"}},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 22, 2026, Richtech\n Robotics Inc., a Nevada corporation (the “ Company ”) received a notice (the “ Notice ”) from the Listing\n Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company is not in compliance\n with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”), because it has not timely filed its Quarterly Report on Form 10-Q\n for the period ended March 31, 2026 (the “ Form 10-Q ”) with the U.S. Securities and Exchange Commission (the “ SEC ”). The\n Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Com","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm"}},{"accession":"0001493152-26-025433","ticker":"SONM","company_name":"DNA X, Inc.","filed_at":"2026-05-27T20:35:28+00:00","headline":"DNA X receives Nasdaq delisting notice; issues $3.05M convertible note to insider","event_type":"regulatory","sec_items":["1.01","2.03","3.01","3.02","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025433","json":"https://secwatch.observer/filing/0001493152-26-025433.json","markdown":"https://secwatch.observer/filing/0001493152-26-025433.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/0001493152-26-025433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests\na hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/0001493152-26-025433-index.htm"}},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying\nit that Nasdaq has initiated a process which could result in the delisting of the Company’s secu","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm"}},{"accession":"0001493152-26-025244","ticker":"XHLD","company_name":"TEN Holdings, Inc.","filed_at":"2026-05-26T20:05:22+00:00","headline":"TEN Holdings receives Nasdaq equity deficiency notice; issues 500k shares for $500k","event_type":"regulatory","sec_items":["1.01","3.01","3.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025244","json":"https://secwatch.observer/filing/0001493152-26-025244.json","markdown":"https://secwatch.observer/filing/0001493152-26-025244.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/0001493152-26-025244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 26, 2026, the Company received a deficiency letter from the Listing Qualifications Department (the “ Staff ”)\nof The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in compliance with Nasda","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030954/000149315226025244/0001493152-26-025244-index.htm"}},{"accession":"0001836875-26-000036","ticker":"NVVE","company_name":"Nuvve Holding Corp.","filed_at":"2026-05-22T22:35:13+00:00","headline":"Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001836875-26-000036","json":"https://secwatch.observer/filing/0001836875-26-000036.json","markdown":"https://secwatch.observer/filing/0001836875-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/nvve-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm"}},{"accession":"0001493152-26-025090","ticker":"GITS","company_name":"Global Interactive Technologies, Inc.","filed_at":"2026-05-22T21:29:03+00:00","headline":"GITS receives Nasdaq delinquency notice for late Q1 10-Q and unfiled 2025 10-K","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025090","json":"https://secwatch.observer/filing/0001493152-26-025090.json","markdown":"https://secwatch.observer/filing/0001493152-26-025090.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1911545/000149315226025090/0001493152-26-025090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1911545/000149315226025090/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm","comparable_excerpt":"May 21, 2026, Global Interactive Technologies, Inc. (the “ Company ”)\nreceived a delinquency compliance alert notice (the “ Notice ”) from the Staff of the Listing Qualifications Department\n(the “ Staff ”) of The Nasdaq","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1911545/000149315226025090/0001493152-26-025090-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}